Purpose: MicroRNAs are small noncoding RNAs that regulate gene expression at the posttranscriptional level. We reported that levels of microRNA (miR)-29 family are decreased in corneas of patients with Fuchs endothelial corneal dystrophy (FECD). The miR-29 family regulates the production of extracellular matrix (ECM) proteins. Accumulation of ECM proteins in Descemet membrane is an important pathologic change in FECD. In this study, we transfected miR-29b into human corneal endothelial cells and tissues and evaluated ECM protein expression levels.
F
uchs endothelial corneal dystrophy (FECD) is a leading cause for corneal transplantation in the United States and worldwide. [1] [2] [3] [4] Corneal transplantation has been the only definitive treatment for FECD, although newer, nonsurgical treatments seem promising. 5 Recent studies have indicated important roles for a variety of pathophysiologic processes in FECD, including oxidative stress, unfolded protein response activation, endoplasmic reticulum stress, autophagy, and apoptosis. [6] [7] [8] [9] [10] [11] [12] MicroRNAs are small (;22 nucleotides), singlestranded RNAs regulating eukaryotic gene expression at the posttranscriptional level. 13, 14 They cause mRNA destabilization and cleavage or direct translational repression. 13 These short RNAs are predicted to regulate as many as 60% of human protein-coding genes with a given microRNA potentially binding up to 4500 human gene targets within 39 untranslated regions. 13 In nonocular tissue, a role for microRNA-29b (miR29b) as a regulator of fibrosis including extracellular matrix (ECM) expression control [15] [16] [17] [18] [19] [20] has been proposed. It also has been shown that miR-29 plays a critical role in the pathology of eye diseases, including pterygium, 21 cataract, 22 glaucoma, [23] [24] [25] and FECD. 26 In trabecular meshwork cells, miR-29 is a critical regulator of ECM expression. [23] [24] [25] We have previously described a comparison of miRNA profiles between FECD and normal corneal endothelial cells and demonstrated widespread miRNA downregulation in FECD. 26 In particular, endothelial expression of miR-29 family members was decreased, which might contribute to increased subendothelial ECM accumulation in FECD. 26 In FECD patient corneas, it is known that components of abnormal ECM excrescences (guttae) include collagen type 1 alpha 1 (COL1A1), collagen type 4 alpha 1 (COL4A1), and laminin gamma 1 (LAMC1). 27, 28 Thus, we hypothesized that miR-29 replacement could be a potential target of future conservative therapeutic approaches in FECD. To this end, we investigated the effects of overexpressing microRNA-29b on ECM protein expression levels in immortalized cells and normal human corneal endothelial tissue.
MATERIALS AND METHODS

Cell Culture
An immortalized FECD human corneal endothelial cell line (iFECD) was established by infection of an FECD patient's corneal endothelial cells with hTERT lentivirus. Culture and use of human FECD cells was conducted after receiving informed consent from the patient via a Johns Hopkins Medicine Institutional Review Board-approved protocol (NA_00023119). iFECD was seeded in culture dishes with OptiMEM-1 (ThermoFisher Scientific, Waltham, MA) supplemented with 8% fetal calf serum, antibiotic/antimycotic solution (10,000 units penicillin (base), 10,000 mg streptomycin (base), and 25 mg of amphotericin B/mL) (Invitrogen, Grand Island, NY), 50 mg/mL gentamicin (Invitrogen), 5 ng/mL epidermal growth factor, 20 ng/mL nerve growth factor, 100 mg bovine pituitary extract, 20 mg/mL ascorbic acid, 200 mg/L calcium chloride, and 0.08% chondroitin sulfate. The medium was changed every 2 days until the cells reached confluence.
Transfection of miR-29b Psh to iFECD
MiR-29b mimic containing a short hairpin structure with a stem loop (miR-29b Psh; Bonac, Fukuoka, Japan) was used in this study. The stem loop contained proline derivatives similar to PnkRNA, as previously described. 29 MiR-29b was transfected into iFECD using miR-29b Psh with lipofectamine RNAiMAX (Invitrogen, San Diego, CA) using standard protocols. The iFECD cells were seeded in 6-well plates (5 · 10 5 cells per well) at 50% confluency and were used at 70% for transfection the next day. The miR-29b Psh (150 mL) and lipofectamine (150 mL) were mixed and added to 3 mL culture media in each well, followed by incubation at 37°C. Final concentration of miR-29b Psh was 100 nM. After 48 hours incubation, total RNA and protein were extracted as described below.
Transfection of miR-29b Psh to Human Corneal Tissue
Six human corneas from 3 donors were obtained from Lions VisionGift (Portland, OR). Corneas were maintained in preservation media (Optisol-GS; Bausch & Lomb, Rochester, NY) at 4°C. Standard eye bank protocol for informed consent and for protection of donor confidentiality was used. The donor corneas were unsuitable for transplantation. Each cornea was divided into halves and incubated at 37°C for transfection. As with the case of iFECD transfection, cell culture medium containing Pshlipofectamine complex (Psh final concentration was 100 nM) was used. After 48 hours incubation, Descemet membrane with endothelial cells was stripped and protein was extracted for Western blot.
Reverse Transcriptase-Polymerase Chain Reaction
Total RNA samples were extracted from cultured cells using the RNeasy Mini Kit (Qiagen, Venlo, Netherlands). Complementary DNA samples were synthesized using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) and Taqman MicroRNA Reverse Transcription Kit (Applied Biosystems). Quantitative reverse transcriptasepolymerase chain reaction (RT-PCR) was performed using TaqMan Universal Master Mix II, no UNG (Applied Biosystems), preamplified cDNA products (diluted 1:20; 5 mL), nuclease-free water, and human-specific primers (Applied Biosystems; Table 1 ) in a 20-mL reaction volume. A notemplate control was included in each experiment to confirm the absence of DNA contamination. All assays used similar amplification efficiency, and a DC T experimental design was used for relative quantification. Data analysis was performed using StepOne software (version 2.2, Applied Biosystems). COL1A1, COL4A1, and LAMC1 were normalized to GAPDH, whereas miR-29b was normalized to RNU48.
Western Blot
After miR-29b transfection, cultured cells and endothelial cells from corneal tissue were lysed with ice-cold Tissue Protein Extraction Reagent (Thermo Fisher Scientific) supplemented with protease inhibitor (1%) and ethylenediaminetetraacetic acid (1%). Total protein concentration was measured using a protein assay kit (Thermo Fisher Scientific), and each sample was adjusted to 20 mg/mL. Proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Mini-PROTEAN TGX Gels; Bio-Rad, Hercules, CA) and transferred to polyvinylidene difluoride 
Statistical Analysis
Statistical analysis was performed using JMP (version 12.1.0; SAS, Cary, NC). RT-PCR and Western blot results were compared using the 2-tailed Student t test. P values less than 0.05 were considered significant.
RESULTS
Psh miR-29b-Induced miR-29b Overexpression in iFECD
Control Psh or miR-29b Psh was transfected into iFECD with lipofectamine. Forty-eight hours later, transfected cells were collected, and miR-29b expression was measured using RT-PCR. Compared with the control group, miR-29b expression level in miR-29b Psh-transfected cells was increased 328.7% (645.7%) (P = 0.004) (Fig. 1) .
ECM mRNA and Protein Expression Were Decreased in iFECD Overexpressing miR-29b
ECM gene expression levels by RT-PCR in immortalized Fuchs corneal endothelial cells transfected with miR29b Psh were significantly decreased to the following percent of expression levels relative to control Psh-transfected cells (mean 6 SD): COL1A1: 1.9% (60.4%) (P = 0.021); COL4A1: 7.1% (61.7%) (P = 0.035); and LAMC1: 21.5% (62.7%) (P = 0.007) (Fig. 2A) . ECM protein expression levels in iFECD transfected with miR-29b Psh were significantly decreased to the following percent of expression levels in control Psh-transfected cells (mean 6 SD): COL1A1: 4.8% (63.2%) (P = 0.001); COL4A1: 42.5% (625.0%) (P = 0.038); and LAMC1: 44.8% (63.1%) (P = 0.011) (Figs. 2-D) . 
LAMC1 Protein Expression in Human Corneal Endothelium In Situ Was Decreased After miR-29b Psh Transfection
We sought to determine the effects of miR-29b Psh transfection into human corneal endothelium in situ. Human corneoscleral tissue was transfected with miR-29b Psh for 48 hours, and stripped Descemet membrane/endothelium was used for Western blot analysis. LAMC1 protein expression level in corneal endothelium transfected with miR-29b Psh was significantly decreased to 14.4% (620.5%) of control Psh-transfected corneal endothelium (P = 0.017, Figs. 3A, B) .
DISCUSSION
MicroRNAs regulate eukaryotic gene expression through mRNA destabilization and cleavage or direct translational repression. 13, 14 These short RNAs are considered important regulators of gene expression in normal and some disease states. Thus, they could represent potentially attractive therapeutic targets.
The present study investigated the effects of overexpression of miR-29b on ECM mRNA and protein levels in iFECD and human corneal endothelium. First, miR-29b expression was increased using miR-29b Psh transfection in iFECD. Overexpressed miR-29b in iFECD downregulated ECM expression. Furthermore, using ex vivo human corneal tissue, overexpression of miR-29b also downregulated ECM expression in corneal endothelium. The latter finding supports the potential feasibility of modifying miR-29b levels in vivo to alter ECM protein production.
Our previous study profiling miRNAs between FECD and normal endothelial cells demonstrated widespread miR-NA downregulation in FECD including significant effects on the miR-29 family. 26 This finding was associated in FECD corneas with increased subendothelial accumulation of ECM proteins, which are targets of miR-29. 26 Furthermore, decreased endothelial expression of DICER1, an important component of miRNA biogenesis, was demonstrated. These results raise the interesting possibility that altered miRNA biogenesis caused by a decrease in DICER1 may contribute to reduction of miRNA abundance. Recent studies demonstrate cytotoxicity of DICER1 depletion in various tissues, and this downregulation may be triggered by oxidative stress. [30] [31] [32] These findings suggest the interesting possibility that oxidative stress in FECD may contribute to DICER1 depletion and a subsequent decrease in miRNA levels with further consequences in FECD pathogenesis. 9 In the early-onset form of FECD, it has been shown that missense mutations Q455K and L450W in the gene encoding the a2 subunit of collagen type 8 alpha 2 (COL8A2) are associated with disease pathogenesis, 27, 33 and collagen type 8 is a component of guttae. 34 Although the a1 subunit of collagen type 8 has been reported to be regulated by miR-29b, 35 to our knowledge, COL8A2 is not described as a miR-29b target.
In this study, we successfully transfected miR-29b into human corneal endothelial cells by incubation with miR-29b Psh. This result suggests that miR-29b could form the basis of an efficient treatment of FECD in the future. Presently, miRNA-based therapies for a variety of diseases are in preclinical or clinical trial stages. 36 Potential approaches for FECD treatment could include delivery of oligonucleotides, plasmids, or adeno-associated virus encoding miR-29b via topical or intracameral route. 36 Increased ECM protein expression is a hallmark feature of FECD. In the present study, miR-29b Psh was used to transfect iFECD and human corneal tissue, resulting in reduced ECM protein expression. Because the Psh platform is DICER independent, we hypothesize that any potential decrease in DICER levels in these cells would not affect the ability to overexpress miR-29b. Thus, miR-29b Psh therapy could be a feasible approach for future FECD treatment and warrants further study. 
